Single User License
INR 134840
Site License
INR 269680
Corporate User License
INR 404520

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Myocardial Infarction-Pipeline Review, H1 2015

Myocardial Infarction-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Myocardial Infarction-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Myocardial Infarction-Pipeline Review, H1 2015', provides an overview of the Myocardial Infarction's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Myocardial Infarction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Infarction and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Myocardial Infarction

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Myocardial Infarction and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Myocardial Infarction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Myocardial Infarction pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Myocardial Infarction

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Myocardial Infarction pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Myocardial Infarction Overview 11

Therapeutics Development 12

Pipeline Products for Myocardial Infarction-Overview 12

Pipeline Products for Myocardial Infarction-Comparative Analysis 13

Myocardial Infarction-Therapeutics under Development by Companies 14

Myocardial Infarction-Therapeutics under Investigation by Universities/Institutes 20

Myocardial Infarction-Pipeline Products Glance 22

Late Stage Products 22

Clinical Stage Products 23

Early Stage Products 24

Unknown Stage Products 25

Myocardial Infarction-Products under Development by Companies 26

Myocardial Infarction-Products under Investigation by Universities/Institutes 32

Myocardial Infarction-Companies Involved in Therapeutics Development 34

A. Menarini Industrie Farmaceutiche Riunite Srl 34

Alligator Bioscience AB 35

Amarantus Bioscience Holdings, Inc. 36

Angion Biomedica Corp. 37

Aprogen, Inc. 38

APT Therapeutics, Inc. 39

AstraZeneca PLC 40

Athersys, Inc. 41

Bayer AG 42

Bharat Biotech International Limited 43

BioLineRx, Ltd. 44

Biscayne Pharmaceuticals, Inc. 45

Cardio3 BioSciences SA 46

Cellmid Limited 47

CellProthera 48

Compugen Ltd. 49

CSL Limited 50

FibroGen, Inc. 51

Fina Biotech 52

Genextra S.p.a. 53

GlaxoSmithKline plc 54

GliaMed, Inc. 55

Hadasit Medical Research Services & Development Ltd 56

Human Stem Cells Institute 57

HUYA Bioscience International, LLC 58

Immune Pharmaceuticals, Ltd. 59

Inbiopro Solutions Pvt. Ltd. 60

Juventas Therapeutics, Inc. 61

Laboratoires Pierre Fabre SA 62

Lacer, S.A. 63

Lee's Pharmaceutical Holdings Limited 64

LegoChem Biosciences, Inc 65

LG Life Sciences, Ltd. 66

Ligand Pharmaceuticals, Inc. 67

Medestea Research & Production S.p.A. 68

Merck & Co., Inc. 69

Mesoblast Limited 70

miRagen Therapeutics, Inc. 71

NeoStem, Inc. 72

NeuroVive Pharmaceutical AB 73

Omeros Corporation 74

Omni Bio Pharmaceutical Inc. 75

Pluristem Therapeutics Inc. 76

Polyphor Ltd. 77

Quantum Genomics SA 78

Recardio GmbH 79

Remedy Pharmaceuticals, Inc. 80

Serodus ASA 81

STELIS Biopharma Pvt. Ltd. 82

Stemedica Cell Technologies, Inc. 83

Stempeutics Research Private Limited 84

TaiGen Biotechnology Co., Ltd. 85

Targazyme, Inc. 86

Vicore Pharma AB 87

Zydus Cadila Healthcare Limited 88

Myocardial Infarction-Therapeutics Assessment 89

Assessment by Monotherapy Products 89

Assessment by Target 90

Assessment by Mechanism of Action 94

Assessment by Route of Administration 97

Assessment by Molecule Type 99

Drug Profiles 101

ADC-1004-Drug Profile 101

Alpha-1 Antitrypsin-Drug Profile 102

amediplase-Drug Profile 104

AMR-001-Drug Profile 105

AMRS-001-Drug Profile 107

ANG-4011-Drug Profile 109

AP-102-Drug Profile 110

APT-102-Drug Profile 111

Biglycan Therapy for Cardiovascular Diseases-Drug Profile 113

Biosimilar 3 for Rheumatoid Arthritis and Acute Myocardial Infarction-Drug Profile 114

Biosimilar 4 for Acute Myocardial Infarction and Infertility-Drug Profile 115

BIS-5409-Drug Profile 116

BL-7060-Drug Profile 117

Bone Marrow Derived Mononuclear Cells for Cardiovascular Diseases-Drug Profile 119

BQ-123-Drug Profile 121

burixafor-Drug Profile 123

C-21-Drug Profile 125

C3BSGQR-3-Drug Profile 127

C3BSGQR-4-Drug Profile 128

CAP-1001-Drug Profile 129

CAP-1002-Drug Profile 130

cenderitide-Drug Profile 132

CGEN-856-Drug Profile 134

CGEN-856S-Drug Profile 135

CGEN-857-Drug Profile 137

CIGB-500-Drug Profile 138

clopidogrel bisulfate-Drug Profile 139

CM-1-Drug Profile 140

CMK-103-Drug Profile 142

Cryocell-Drug Profile 143

CSL-112-Drug Profile 144

CTX-101-Drug Profile 145

CTX-201-Drug Profile 146

Drugs to Inhibit Alpha Myosin for Cardiovascular Disorders-Drug Profile 147

Drugs to Inhibit Sir2 Protein for Ischemic Stroke and Myocardial Infarction-Drug Profile 148

Ephrin A-1-Drug Profile 149

F-573-Drug Profile 150

Fc-Alpha-1 Antitrypsin-Drug Profile 151

FcAAT-2-Drug Profile 152

FcAAT-3-Drug Profile 153

FG-6874-Drug Profile 154

Gemacell-Drug Profile 155

Gene Therapy for Acute Myocardial Infarction-Drug Profile 156

glyburide-Drug Profile 157

GM-1485-Drug Profile 159

HBI-3802-Drug Profile 161

HYPER-IL-6-Drug Profile 162

IBPB-005ET-Drug Profile 163

ICG-001-Drug Profile 164

JI-38-Drug Profile 165

JVS-100-Drug Profile 166

JVS-200-Drug Profile 168

LA-8045-Drug Profile 169

LC-280126-Drug Profile 170

losmapimod-Drug Profile 172

Mesenchymal Stem Cells-Drug Profile 174

MGN-1374-Drug Profile 176

MGN-6114-Drug Profile 177

Monoclonal Antibody Conjugates to Target Mannose Receptor for Myocardial Infarction-Drug Profile 178

Monoclonal Antibody to Inhibit CD20 for Cardiovascular Disease-Drug Profile 179

MPC-150IM-Drug Profile 180

MTP-131-Drug Profile 182

MultiStem-Drug Profile 184

NL-005-Drug Profile 187

NVP-019-Drug Profile 188

Oligonucleotide for Oncology and Cardiovascular-Drug Profile 189

Oligonucleotides for Cardiometabolic Diseases and Renal diseases-Drug Profile 190

OMS-721-Drug Profile 191

Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction-Drug Profile 193

POL-6326-Drug Profile 194

Polyglactin 370 for Acute Myocardial Infarction-Drug Profile 196

ProtheraCytes-Drug Profile 197

QGC-101-Drug Profile 199

REC-01-Drug Profile 200

Recombinant Protein for Myocardial Infarction-Drug Profile 201

Recombinant Protein to Agonize IGF-1R for Myocardial Infarction-Drug Profile 202

remestemcel-L-Drug Profile 203

rivaroxaban-Drug Profile 206

RNAi Oligonucleotide for Myocardial Infarction-Drug Profile 211

RNAi Oligonucleotide for Myocardial Infarction-Drug Profile 212

SBL-004-Drug Profile 213

SER-130-Drug Profile 214

Small Molecule for Myocardial Infarction-Drug Profile 215

Small Molecule to Inhibit Blood Factor XIa for CAHD and Stroke-Drug Profile 216

Small Molecules for Myocardial Infarction and Inflammation-Drug Profile 217

Small Molecules to Antagonize Adenosine A2B Receptor for Asthma and Myocardial Infarction-Drug Profile 218

Small Molecules to Inhibit MMP for Myocardial Infarction-Drug Profile 219

Small Molecules to Inhibit mPTP for Cardiovascular and Neurodegenerative Diseases-Drug Profile 220

Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders-Drug Profile 221

Small Molecules to Inhibit TNF-a for Cardiovascular and CNS Disorders-Drug Profile 222

Stem Cell Therapy for Blood and Cardiovascular Diseases-Drug Profile 223

Stem Cell Therapy for Cardiovascular Diseases-Drug Profile 224

Stem Cell Therapy for Myocardial Infarction-Drug Profile 226

Stem Cell Therapy for Myocardial Infarction-Drug Profile 228

Stem Cells for Acute Myocardial Infarction-Drug Profile 229

Stempeucel-Drug Profile 230

Synthetic Peptide for Cardiovascular Diseases-Drug Profile 233

THR-100-Drug Profile 234

ticagrelor-Drug Profile 236

TZ-101-Drug Profile 240

VN-100-Drug Profile 242

ZK-001-Drug Profile 243

Myocardial Infarction-Recent Pipeline Updates 245

Myocardial Infarction-Dormant Projects 312

Myocardial Infarction-Discontinued Products 318

Myocardial Infarction-Product Development Milestones 319

Featured News & Press Releases 319

Appendix 330

Methodology 330

Coverage 330

Secondary Research 330

Primary Research 330

Expert Panel Validation 330

Contact Us 330

Disclaimer 331

List of Tables

Number of Products under Development for Myocardial Infarction, H1 2015 19

Number of Products under Development for Myocardial Infarction-Comparative Analysis, H1 2015 20

Number of Products under Development by Companies, H1 2015 22

Number of Products under Development by Companies, H1 2015 (Contd..1) 23

Number of Products under Development by Companies, H1 2015 (Contd..2) 24

Number of Products under Development by Companies, H1 2015 (Contd..3) 25

Number of Products under Development by Companies, H1 2015 (Contd..4) 26

Number of Products under Investigation by Universities/Institutes, H1 2015 28

Comparative Analysis by Late Stage Development, H1 2015 29

Comparative Analysis by Clinical Stage Development, H1 2015 30

Comparative Analysis by Early Stage Development, H1 2015 31

Comparative Analysis by Unknown Stage Development, H1 2015 32

Products under Development by Companies, H1 2015 33

Products under Development by Companies, H1 2015 (Contd..1) 34

Products under Development by Companies, H1 2015 (Contd..2) 35

Products under Development by Companies, H1 2015 (Contd..3) 36

Products under Development by Companies, H1 2015 (Contd..4) 37

Products under Development by Companies, H1 2015 (Contd..5) 38

Products under Investigation by Universities/Institutes, H1 2015 39

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 40

Myocardial Infarction-Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 41

Myocardial Infarction-Pipeline by Alligator Bioscience AB, H1 2015 42

Myocardial Infarction-Pipeline by Amarantus Bioscience Holdings, Inc., H1 2015 43

Myocardial Infarction-Pipeline by Angion Biomedica Corp., H1 2015 44

Myocardial Infarction-Pipeline by Aprogen, Inc., H1 2015 45

Myocardial Infarction-Pipeline by APT Therapeutics, Inc., H1 2015 46

Myocardial Infarction-Pipeline by AstraZeneca PLC, H1 2015 47

Myocardial Infarction-Pipeline by Athersys, Inc., H1 2015 48

Myocardial Infarction-Pipeline by Bayer AG, H1 2015 49

Myocardial Infarction-Pipeline by Bharat Biotech International Limited, H1 2015 50

Myocardial Infarction-Pipeline by BioLineRx, Ltd., H1 2015 51

Myocardial Infarction-Pipeline by Biscayne Pharmaceuticals, Inc., H1 2015 52

Myocardial Infarction-Pipeline by Cardio3 BioSciences SA, H1 2015 53

Myocardial Infarction-Pipeline by Cellmid Limited, H1 2015 54

Myocardial Infarction-Pipeline by CellProthera, H1 2015 55

Myocardial Infarction-Pipeline by Compugen Ltd., H1 2015 56

Myocardial Infarction-Pipeline by CSL Limited, H1 2015 57

Myocardial Infarction-Pipeline by FibroGen, Inc., H1 2015 58

Myocardial Infarction-Pipeline by Fina Biotech, H1 2015 59

Myocardial Infarction-Pipeline by Genextra S.p.a., H1 2015 60

Myocardial Infarction-Pipeline by GlaxoSmithKline plc, H1 2015 61

Myocardial Infarction-Pipeline by GliaMed, Inc., H1 2015 62

Myocardial Infarction-Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2015 63

Myocardial Infarction-Pipeline by Human Stem Cells Institute, H1 2015 64

Myocardial Infarction-Pipeline by HUYA Bioscience International, LLC, H1 2015 65

Myocardial Infarction-Pipeline by Immune Pharmaceuticals, Ltd., H1 2015 66

Myocardial Infarction-Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 67

Myocardial Infarction-Pipeline by Juventas Therapeutics, Inc., H1 2015 68

Myocardial Infarction-Pipeline by Laboratoires Pierre Fabre SA, H1 2015 69

Myocardial Infarction-Pipeline by Lacer, S.A., H1 2015 70

Myocardial Infarction-Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 71

Myocardial Infarction-Pipeline by LegoChem Biosciences, Inc, H1 2015 72

Myocardial Infarction-Pipeline by LG Life Sciences, Ltd., H1 2015 73

Myocardial Infarction-Pipeline by Ligand Pharmaceuticals, Inc., H1 2015 74

Myocardial Infarction-Pipeline by Medestea Research & Production S.p.A., H1 2015 75

Myocardial Infarction-Pipeline by Merck & Co., Inc., H1 2015 76

Myocardial Infarction-Pipeline by Mesoblast Limited, H1 2015 77

Myocardial Infarction-Pipeline by miRagen Therapeutics, Inc., H1 2015 78

Myocardial Infarction-Pipeline by NeoStem, Inc., H1 2015 79

Myocardial Infarction-Pipeline by NeuroVive Pharmaceutical AB, H1 2015 80

Myocardial Infarction-Pipeline by Omeros Corporation, H1 2015 81

Myocardial Infarction-Pipeline by Omni Bio Pharmaceutical Inc., H1 2015 82

Myocardial Infarction-Pipeline by Pluristem Therapeutics Inc., H1 2015 83

Myocardial Infarction-Pipeline by Polyphor Ltd., H1 2015 84

Myocardial Infarction-Pipeline by Quantum Genomics SA, H1 2015 85

Myocardial Infarction-Pipeline by Recardio GmbH, H1 2015 86

Myocardial Infarction-Pipeline by Remedy Pharmaceuticals, Inc., H1 2015 87

Myocardial Infarction-Pipeline by Serodus ASA, H1 2015 88

Myocardial Infarction-Pipeline by STELIS Biopharma Pvt. Ltd., H1 2015 89

Myocardial Infarction-Pipeline by Stemedica Cell Technologies, Inc., H1 2015 90

Myocardial Infarction-Pipeline by Stempeutics Research Private Limited, H1 2015 91

Myocardial Infarction-Pipeline by TaiGen Biotechnology Co., Ltd., H1 2015 92

Myocardial Infarction-Pipeline by Targazyme, Inc., H1 2015 93

Myocardial Infarction-Pipeline by Vicore Pharma AB, H1 2015 94

Myocardial Infarction-Pipeline by Zydus Cadila Healthcare Limited, H1 2015 95

Assessment by Monotherapy Products, H1 2015 96

Number of Products by Stage and Target, H1 2015 98

Number of Products by Stage and Mechanism of Action, H1 2015 102

Number of Products by Stage and Route of Administration, H1 2015 105

Number of Products by Stage and Molecule Type, H1 2015 107

Myocardial Infarction Therapeutics-Recent Pipeline Updates, H1 2015 252

Myocardial Infarction-Dormant Projects, H1 2015 319

Myocardial Infarction-Dormant Projects (Contd..1), H1 2015 320

Myocardial Infarction-Dormant Projects (Contd..2), H1 2015 321

Myocardial Infarction-Dormant Projects (Contd..3), H1 2015 322

Myocardial Infarction-Dormant Projects (Contd..4), H1 2015 323

Myocardial Infarction-Dormant Projects (Contd..5), H1 2015 324

Myocardial Infarction-Discontinued Products, H1 2015 325

List of Figures

Number of Products under Development for Myocardial Infarction, H1 2015 19

Number of Products under Development for Myocardial Infarction-Comparative Analysis, H1 2015 20

Number of Products under Development by Companies, H1 2015 21

Number of Products under Investigation by Universities/Institutes, H1 2015 27

Comparative Analysis by Late Stage Development, H1 2015 29

Comparative Analysis by Clinical Stage Development, H1 2015 30

Comparative Analysis by Early Stage Products, H1 2015 31

Assessment by Monotherapy Products, H1 2015 96

Number of Products by Top 10 Targets, H1 2015 97

Number of Products by Stage and Top 10 Targets, H1 2015 97

Number of Products by Top 10 Mechanism of Actions, H1 2015 101

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 101

Number of Products by Top 10 Routes of Administration, H1 2015 104

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 104

Number of Products by Top 10 Molecule Types, H1 2015 106

Number of Products by Stage and Top 10 Molecule Types, H1 2015 106

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

A. Menarini Industrie Farmaceutiche Riunite Srl

Alligator Bioscience AB

Amarantus Bioscience Holdings, Inc.

Angion Biomedica Corp.

Aprogen, Inc.

APT Therapeutics, Inc.

AstraZeneca PLC

Athersys, Inc.

Bayer AG

Bharat Biotech International Limited

BioLineRx, Ltd.

Biscayne Pharmaceuticals, Inc.

Cardio3 BioSciences SA

Cellmid Limited

CellProthera

Compugen Ltd.

CSL Limited

FibroGen, Inc.

Fina Biotech

Genextra S.p.a.

GlaxoSmithKline plc

GliaMed, Inc.

Hadasit Medical Research Services & Development Ltd

Human Stem Cells Institute

HUYA Bioscience International, LLC

Immune Pharmaceuticals, Ltd.

Inbiopro Solutions Pvt. Ltd.

Juventas Therapeutics, Inc.

Laboratoires Pierre Fabre SA

Lacer, S.A.

Lee's Pharmaceutical Holdings Limited

LegoChem Biosciences, Inc

LG Life Sciences, Ltd.

Ligand Pharmaceuticals, Inc.

Medestea Research & Production S.p.A.

Merck & Co., Inc.

Mesoblast Limited

miRagen Therapeutics, Inc.

NeoStem, Inc.

NeuroVive Pharmaceutical AB

Omeros Corporation

Omni Bio Pharmaceutical Inc.

Pluristem Therapeutics Inc.

Polyphor Ltd.

Quantum Genomics SA

Recardio GmbH

Remedy Pharmaceuticals, Inc.

Serodus ASA

STELIS Biopharma Pvt. Ltd.

Stemedica Cell Technologies, Inc.

Stempeutics Research Private Limited

TaiGen Biotechnology Co., Ltd.

Targazyme, Inc.

Vicore Pharma AB

Zydus Cadila Healthcare Limited

Myocardial Infarction Therapeutic Products under Development, Key Players in Myocardial Infarction Therapeutics, Myocardial Infarction Pipeline Overview, Myocardial Infarction Pipeline, Myocardial Infarction Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com